-
1
-
-
77955255788
-
Molecular diversity of VEGF-A as a regulator of its biological activity
-
J. Woolard, H.S. Bevan, S.J. Harper, and D.O. Bates Molecular diversity of VEGF-A as a regulator of its biological activity Microcirculation 16 2009 572 592
-
(2009)
Microcirculation
, vol.16
, pp. 572-592
-
-
Woolard, J.1
Bevan, H.S.2
Harper, S.J.3
Bates, D.O.4
-
2
-
-
84858079914
-
PI3K/AKT/mTOR pathway in angiogenesis
-
J. Karar, and A. Maity PI3K/AKT/mTOR pathway in angiogenesis Front. Mol. Neurosci. 4 2011 51
-
(2011)
Front. Mol. Neurosci.
, vol.4
, pp. 51
-
-
Karar, J.1
Maity, A.2
-
3
-
-
33846879810
-
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma
-
W.G. Kaelin Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma Clin. Cancer Res. 13 2007 680s 684s
-
(2007)
Clin. Cancer Res.
, vol.13
-
-
Kaelin Jr., W.G.1
-
4
-
-
0034650744
-
Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
-
J. Rak, Y. Mitsuhashi, C. Sheehan, A. Tamir, A. Vioria-Petit, J. Filmus, S.J. Mansour, N.G. Ahn, and R.S. Kerbel Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras transformed epithelial cells and fibroblasts Cancer Res. 60 2000 490 498 (Pubitemid 30070780)
-
(2000)
Cancer Research
, vol.60
, Issue.2
, pp. 490-498
-
-
Rak, J.1
Mitsuhashi, Y.2
Sheehan, C.3
Tamir, A.4
Viloria-Petit, A.5
Filmus, J.6
Mansour, S.J.7
Ahn, N.G.8
Kerbel, R.S.9
-
5
-
-
0028834638
-
Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
-
S. Grugel, G. Finkenzeller, K. Weindel, B. Barleon, and D. Marmé Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells J. Biol. Chem. 270 1995 25915 25919
-
(1995)
J. Biol. Chem.
, vol.270
, pp. 25915-25919
-
-
Grugel, S.1
Finkenzeller, G.2
Weindel, K.3
Barleon, B.4
Marmé, D.5
-
6
-
-
0032541029
-
P42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts
-
DOI 10.1074/jbc.273.29.18165
-
J. Milanini, F. Vinals, J. Pouysségur, and G. Pagès p42/p44 MAP kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts J. Biol. Chem. 273 1998 18165 18172 (Pubitemid 28334735)
-
(1998)
Journal of Biological Chemistry
, vol.273
, Issue.29
, pp. 18165-18172
-
-
Milanini, J.1
Vinals, F.2
Pouyssegur, J.3
Pages, G.4
-
7
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
8
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
DOI 10.1056/NEJMoa061884
-
A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, and D.H. Johnson Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 355 2006 2542 2550 (Pubitemid 44917502)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
9
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
DOI 10.1016/S0140-6736(07)61904-7, PII S0140673607619047
-
B. Escudier, A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J.O. Bay, I. Bodrogi, A. Jagiello-Gruszfeld, and N. Moore Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
-
(2007)
Lancet
, vol.370
, Issue.9605
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.-O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
10
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, and T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
Mikkelsen, T.4
Schiff, D.5
Abrey, L.E.6
Yung, W.K.7
Paleologos, N.8
Nicholas, M.K.9
Jensen, R.10
Vredenburgh, J.11
Huang, J.12
Zheng, M.13
Cloughesy, T.14
-
11
-
-
59949083263
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
-
T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. Mackey, J.A. Butman, K. Camphausen, J. Park, P.S. Albert, and H.A. Fine Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J. Clin. Oncol. 27 2009 740 745
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 740-745
-
-
Kreisl, T.N.1
Kim, L.2
Moore, K.3
Duic, P.4
Royce, C.5
Stroud, I.6
Garren, N.7
MacKey, M.8
Butman, J.A.9
Camphausen, K.10
Park, J.11
Albert, P.S.12
Fine, H.A.13
-
12
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, R.S. Mannel, H.D. Homesley, J. Fowler, B.E. Greer, M. Boente, M.J. Birrer, and S.X. Liang Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 2011 2473 2483
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
Fleming, G.F.4
Monk, B.J.5
Huang, H.6
Mannel, R.S.7
Homesley, H.D.8
Fowler, J.9
Greer, B.E.10
Boente, M.11
Birrer, M.J.12
Liang, S.X.13
-
13
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, M.S. Carey, P. Beale, A. Cervantes, C. Kurzeder, A. du Bois, J. Sehouli, R. Kimmig, A. Stahle, F. Collinson, S. Essapen, C. Gourley, A. Lortholary, F. Selle, M.R. Mirza, A. Leminen, M. Plante, D. Stark, W. Qian, M.K. Parmar, and A.M. Oza A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 2011 2484 2496
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
Ledermann, J.A.4
Pujade-Lauraine, E.5
Kristensen, G.6
Carey, M.S.7
Beale, P.8
Cervantes, A.9
Kurzeder, C.10
Du Bois, A.11
Sehouli, J.12
Kimmig, R.13
Stahle, A.14
Collinson, F.15
Essapen, S.16
Gourley, C.17
Lortholary, A.18
Selle, F.19
Mirza, M.R.20
Leminen, A.21
Plante, M.22
Stark, D.23
Qian, W.24
Parmar, M.K.25
Oza, A.M.26
more..
-
14
-
-
13444278498
-
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
-
H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res. 65 2005 671 680 (Pubitemid 40216420)
-
(2005)
Cancer Research
, vol.65
, Issue.3
, pp. 671-680
-
-
Gerber, H.-P.1
Ferrara, N.2
-
15
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, E.A. Perez, T. Shenkier, D. Cella, and N.E. Davidson Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N. Engl. J. Med. 357 2007 2666 2676
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
Shenkier, T.7
Cella, D.8
Davidson, N.E.9
-
16
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
DOI 10.1126/science.1104819
-
R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
-
(2005)
Science
, vol.307
, Issue.5706
, pp. 58-62
-
-
Jain, R.K.1
-
17
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, and P.A. Trail BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109 (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
18
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
D.B. Mendel, A.D. Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.O. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J.M. Cherrington In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin. Cancer Res. 9 2003 327 337 (Pubitemid 36109749)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1
, pp. 327-337
-
-
Mendel, D.B.1
Douglas Laird, A.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
19
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, and J. Bruix Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
De Oliveira, A.C.7
Santoro, A.8
Raoul, J.L.9
Forner, A.10
Schwartz, M.11
Porta, C.12
Zeuzem, S.13
Bolondi, L.14
Greten, T.F.15
Galle, P.R.16
Seitz, J.F.17
Borbath, I.18
Haussinger, D.19
Giannaris, T.20
Shan, M.21
Moscovici, M.22
Voliotis, D.23
Bruix, J.24
more..
-
20
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
DOI 10.1056/NEJMoa060655
-
B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, and R.M. Bukowski Sorafenib in advanced clear-cell renal-cell carcinoma N. Engl. J. Med. 356 2007 125 134 (Pubitemid 46089673)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
Negrier, S.7
Chevreau, C.8
Solska, E.9
Desai, A.A.10
Rolland, F.11
Demkow, T.12
Hutson, T.E.13
Gore, M.14
Freeman, S.15
Schwartz, B.16
Shan, M.17
Simantov, R.18
Bukowski, R.M.19
-
21
-
-
79951988792
-
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial
-
D. Matei, M.W. Sill, H.A. Lankes, K. DeGeest, R.E. Bristow, D. Mutch, S.D. Yamada, D. Cohn, V. Calvert, J. Farley, E.F. Petricoin, and M.J. Birrer Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial J. Clin. Oncol. 29 2011 69 75
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 69-75
-
-
Matei, D.1
Sill, M.W.2
Lankes, H.A.3
Degeest, K.4
Bristow, R.E.5
Mutch, D.6
Yamada, S.D.7
Cohn, D.8
Calvert, V.9
Farley, J.10
Petricoin, E.F.11
Birrer, M.J.12
-
22
-
-
77954754601
-
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
-
S.K. Williamson, J. Moon, C.H. Huang, P.P. Guaglianone, M. LeBlanc, G.T. Wolf, and S.G. Urba Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420 J. Clin. Oncol. 28 2010 3330 3335
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 3330-3335
-
-
Williamson, S.K.1
Moon, J.2
Huang, C.H.3
Guaglianone, P.P.4
Leblanc, M.5
Wolf, G.T.6
Urba, S.G.7
-
23
-
-
56749098278
-
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
-
M.C. Heinrich, R.G. Maki, C.L. Corless, C.R. Antonescu, A. Harlow, D. Griffith, A. Town, A. McKinley, W.B. Ou, J.A. Fletcher, C.D. Fletcher, X. Huang, D.P. Cohen, C.M. Baum, and G.D. Demetri Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor J. Clin. Oncol. 26 2008 5352 5359
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5352-5359
-
-
Heinrich, M.C.1
Maki, R.G.2
Corless, C.L.3
Antonescu, C.R.4
Harlow, A.5
Griffith, D.6
Town, A.7
McKinley, A.8
Ou, W.B.9
Fletcher, J.A.10
Fletcher, C.D.11
Huang, X.12
Cohen, D.P.13
Baum, C.M.14
Demetri, G.D.15
-
24
-
-
70249084594
-
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
-
B. Escudier, J. Roigas, S. Gillessen, U. Harmenberg, S. Srinivas, S.F. Mulder, G. Fountzilas, C. Peschel, P. Flodgren, E.C. Maneval, I. Chen, and N.J. Vogelzang Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J. Clin. Oncol. 27 2009 4068 4075
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4068-4075
-
-
Escudier, B.1
Roigas, J.2
Gillessen, S.3
Harmenberg, U.4
Srinivas, S.5
Mulder, S.F.6
Fountzilas, G.7
Peschel, C.8
Flodgren, P.9
Maneval, E.C.10
Chen, I.11
Vogelzang, N.J.12
-
25
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.S. Chen, D. Horsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao, and P. Ruszniewski Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 501 513
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
Bang, Y.J.4
Borbath, I.5
Lombard-Bohas, C.6
Valle, J.7
Metrakos, P.8
Smith, D.9
Vinik, A.10
Chen, J.S.11
Horsch, D.12
Hammel, P.13
Wiedenmann, B.14
Van Cutsem, E.15
Patyna, S.16
Lu, D.R.17
Blanckmeister, C.18
Chao, R.19
Ruszniewski, P.20
more..
-
26
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
DOI 10.1056/NEJMoa065044
-
R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S.T. Kim, I. Chen, P.W. Bycott, C.M. Baum, and R.A. Figlin Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 2007 115 124 (Pubitemid 46089672)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
27
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, S. Oudard, S. Negrier, C. Szczylik, R. Pili, G.A. Bjarnason, X. Garcia-del-Muro, J.A. Sosman, E. Solska, G. Wilding, J.A. Thompson, S.T. Kim, I. Chen, X. Huang, and R.A. Figlin Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J. Clin. Oncol. 27 2009 3584 3590
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Oudard, S.6
Negrier, S.7
Szczylik, C.8
Pili, R.9
Bjarnason, G.A.10
Garcia-Del-Muro, X.11
Sosman, J.A.12
Solska, E.13
Wilding, G.14
Thompson, J.A.15
Kim, S.T.16
Chen, I.17
Huang, X.18
Figlin, R.A.19
-
28
-
-
84865556743
-
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
-
K.H. Baumann, A. du Bois, W. Meier, J. Rau, P. Wimberger, J. Sehouli, C. Kurzeder, F. Hilpert, A. Hasenburg, U. Canzler, L.C. Hanker, P. Hillemanns, B. Richter, K. Wollschlaeger, T. Dewitz, D. Bauerschlag, and U. Wagner A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy Ann. Oncol. 23 2012 2265 2271
-
(2012)
Ann. Oncol.
, vol.23
, pp. 2265-2271
-
-
Baumann, K.H.1
Du Bois, A.2
Meier, W.3
Rau, J.4
Wimberger, P.5
Sehouli, J.6
Kurzeder, C.7
Hilpert, F.8
Hasenburg, A.9
Canzler, U.10
Hanker, L.C.11
Hillemanns, P.12
Richter, B.13
Wollschlaeger, K.14
Dewitz, T.15
Bauerschlag, D.16
Wagner, U.17
-
29
-
-
74249122456
-
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184
-
H.J. Mackay, A. Tinker, E. Winquist, G. Thomas, K. Swenerton, A. Oza, J. Sederias, P. Ivy, and E.A. Eisenhauer A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184 Gynecol. Oncol. 116 2010 163 167
-
(2010)
Gynecol. Oncol.
, vol.116
, pp. 163-167
-
-
MacKay, H.J.1
Tinker, A.2
Winquist, E.3
Thomas, G.4
Swenerton, K.5
Oza, A.6
Sederias, J.7
Ivy, P.8
Eisenhauer, E.A.9
-
30
-
-
73949143686
-
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01
-
J.P. Machiels, S. Henry, S. Zanetta, M.C. Kaminsky, N. Michoux, D. Rommel, S. Schmitz, E. Bompas, A.F. Dillies, S. Faivre, A. Moxhon, T. Duprez, and J. Guigay Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 J. Clin. Oncol. 28 2010 21 28
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 21-28
-
-
MacHiels, J.P.1
Henry, S.2
Zanetta, S.3
Kaminsky, M.C.4
Michoux, N.5
Rommel, D.6
Schmitz, S.7
Bompas, E.8
Dillies, A.F.9
Faivre, S.10
Moxhon, A.11
Duprez, T.12
Guigay, J.13
-
31
-
-
33746899015
-
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway
-
DOI 10.1158/1541-7786.MCR-05-0234
-
N. Pore, Z. Jiang, H.K. Shu, E. Bernhard, G.D. Kao, and A. Maity Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway Mol. Cancer Res. 4 2006 471 479 (Pubitemid 44197042)
-
(2006)
Molecular Cancer Research
, vol.4
, Issue.7
, pp. 471-479
-
-
Pore, N.1
Jiang, Z.2
Shu, H.-K.3
Bernhard, E.4
Kao, G.D.5
Maity, A.6
-
32
-
-
0037111665
-
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin
-
DOI 10.1182/blood-2002-01-0109
-
M. Mayerhofer, P. Valent, W.R. Sperr, J.D. Griffin, and C. Sillaber BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin Blood 100 2002 3767 3775 (Pubitemid 35303950)
-
(2002)
Blood
, vol.100
, Issue.10
, pp. 3767-3775
-
-
Mayerhofer, M.1
Valent, P.2
Sperr, W.R.3
Griffin, J.D.4
Sillaber, C.5
-
33
-
-
34548178582
-
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells
-
DOI 10.1074/jbc.M700563200
-
O. Dormond, J.C. Madsen, and D.M. Briscoe The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells J. Biol. Chem. 282 2007 23679 23686 (Pubitemid 47311969)
-
(2007)
Journal of Biological Chemistry
, vol.282
, Issue.32
, pp. 23679-23686
-
-
Dormond, O.1
Madsen, J.C.2
Briscoe, D.M.3
-
34
-
-
0034654174
-
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
-
H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M.M. Georgescu, J.W. Simons, and G.L. Semenza Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Res. 60 2000 1541 1545 (Pubitemid 30183422)
-
(2000)
Cancer Research
, vol.60
, Issue.6
, pp. 1541-1545
-
-
Zhong, H.1
Chiles, K.2
Feldser, D.3
Laughner, E.4
Hanrahan, C.5
Georgescu, M.-M.6
Simons, J.W.7
Semenza, G.L.8
-
36
-
-
0035012605
-
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
-
DOI 10.1128/MCB.21.12.3995-4004.2001
-
E. Laughner, P. Taghavi, K. Chiles, P.C. Mahon, and G.L. Semenza HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol. Cell. Biol. 21 2001 3995 4004 (Pubitemid 32476461)
-
(2001)
Molecular and Cellular Biology
, vol.21
, Issue.12
, pp. 3995-4004
-
-
Laughner, E.1
Taghavi, P.2
Chiles, K.3
Mahon, P.C.4
Semenza, G.L.5
-
37
-
-
30044432434
-
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
-
DOI 10.1038/nm1337
-
G.V. Thomas, C. Tran, I.K. Mellinghoff, D.S. Welsbie, E. Chan, B. Fueger, J. Czernin, and C.L. Sawyers Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat. Med. 12 2006 122 127 (Pubitemid 43050086)
-
(2006)
Nature Medicine
, vol.12
, Issue.1
, pp. 122-127
-
-
Thomas, G.V.1
Tran, C.2
Mellinghoff, I.K.3
Welsbie, D.S.4
Chan, E.5
Fueger, B.6
Czernin, J.7
Sawyers, C.L.8
-
39
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
DOI 10.1056/NEJMoa066838
-
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I.G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, and R.J. Motzer Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N. Engl. J. Med. 356 2007 2271 2281 (Pubitemid 46849157)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
Staroslawska, E.7
Sosman, J.8
McDermott, D.9
Bodrogi, I.10
Kovacevic, Z.11
Lesovoy, V.12
Schmidt-Wolf, I.G.H.13
Barbarash, O.14
Gokmen, E.15
O'Toole, T.16
Lustgarten, S.17
Moore, L.18
Motzer, R.J.19
-
40
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grunwald, J.A. Thompson, R.A. Figlin, N. Hollaender, G. Urbanowitz, W.J. Berg, A. Kay, D. Lebwohl, and A. Ravaud Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
Hutson, T.E.4
Porta, C.5
Bracarda, S.6
Grunwald, V.7
Thompson, J.A.8
Figlin, R.A.9
Hollaender, N.10
Urbanowitz, G.11
Berg, W.J.12
Kay, A.13
Lebwohl, D.14
Ravaud, A.15
-
41
-
-
79953182631
-
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study
-
S.M. Ansell, H. Tang, P.J. Kurtin, P.A. Koenig, D.J. Inwards, K. Shah, S.C. Ziesmer, A.L. Feldman, R. Rao, M. Gupta, C. Erlichman, and T.E. Witzig Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study Lancet Oncol. 12 2011 361 368
-
(2011)
Lancet Oncol.
, vol.12
, pp. 361-368
-
-
Ansell, S.M.1
Tang, H.2
Kurtin, P.J.3
Koenig, P.A.4
Inwards, D.J.5
Shah, K.6
Ziesmer, S.C.7
Feldman, A.L.8
Rao, R.9
Gupta, M.10
Erlichman, C.11
Witzig, T.E.12
-
42
-
-
77954478305
-
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies
-
M.M. Javle, R.T. Shroff, H. Xiong, G.A. Varadhachary, D. Fogelman, S.A. Reddy, D. Davis, Y. Zhang, R.A. Wolff, and J.L. Abbruzzese Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies BMC Cancer 10 2010 368
-
(2010)
BMC Cancer
, vol.10
, pp. 368
-
-
Javle, M.M.1
Shroff, R.T.2
Xiong, H.3
Varadhachary, G.A.4
Fogelman, D.5
Reddy, S.A.6
Davis, D.7
Zhang, Y.8
Wolff, R.A.9
Abbruzzese, J.L.10
-
43
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, P. Tomassetti, M.E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, and K. Oberg Everolimus for advanced pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 514 523
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
Bohas, C.L.4
Wolin, E.M.5
Van Cutsem, E.6
Hobday, T.J.7
Okusaka, T.8
Capdevila, J.9
De Vries, E.G.10
Tomassetti, P.11
Pavel, M.E.12
Hoosen, S.13
Haas, T.14
Lincy, J.15
Lebwohl, D.16
Oberg, K.17
-
44
-
-
78650383149
-
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
-
M.J. Mackenzie, B.I. Rini, P. Elson, A. Schwandt, L. Wood, M. Trinkhaus, G. Bjarnason, and J. Knox Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann. Oncol. 22 2011 145 148
-
(2011)
Ann. Oncol.
, vol.22
, pp. 145-148
-
-
MacKenzie, M.J.1
Rini, B.I.2
Elson, P.3
Schwandt, A.4
Wood, L.5
Trinkhaus, M.6
Bjarnason, G.7
Knox, J.8
-
45
-
-
76549107351
-
Beyond rapalog therapy: Preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2
-
K. Yu, C. Shi, L. Toral-Barza, J. Lucas, B. Shor, J.E. Kim, W.G. Zhang, R. Mahoney, C. Gaydos, L. Tardio, S.K. Kim, R. Conant, K. Curran, J. Kaplan, J. Verheijen, S. Ayral-Kaloustian, T.S. Mansour, R.T. Abraham, A. Zask, and J.J. Gibbons Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 Cancer Res. 70 2010 621 631
-
(2010)
Cancer Res.
, vol.70
, pp. 621-631
-
-
Yu, K.1
Shi, C.2
Toral-Barza, L.3
Lucas, J.4
Shor, B.5
Kim, J.E.6
Zhang, W.G.7
Mahoney, R.8
Gaydos, C.9
Tardio, L.10
Kim, S.K.11
Conant, R.12
Curran, K.13
Kaplan, J.14
Verheijen, J.15
Ayral-Kaloustian, S.16
Mansour, T.S.17
Abraham, R.T.18
Zask, A.19
Gibbons, J.J.20
more..
-
46
-
-
77952300540
-
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
-
B. Escudier, J. Bellmunt, S. Negrier, E. Bajetta, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa, and V. Sneller Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J. Clin. Oncol. 28 2010 2144 2150
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2144-2150
-
-
Escudier, B.1
Bellmunt, J.2
Negrier, S.3
Bajetta, E.4
Melichar, B.5
Bracarda, S.6
Ravaud, A.7
Golding, S.8
Jethwa, S.9
Sneller, V.10
-
47
-
-
84857626952
-
Bevacizumab in the treatment of metastatic breast cancer: Friend or foe?
-
A.J. Montero, M. Escobar, G. Lopes, S. Gluck, and C. Vogel Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr. Oncol. Rep. 14 2012 1 11
-
(2012)
Curr. Oncol. Rep.
, vol.14
, pp. 1-11
-
-
Montero, A.J.1
Escobar, M.2
Lopes, G.3
Gluck, S.4
Vogel, C.5
-
48
-
-
79551521053
-
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08
-
C.J. Allegra, G. Yothers, M.J. O'Connell, S. Sharif, N.J. Petrelli, L.H. Colangelo, J.N. Atkins, T.E. Seay, L. Fehrenbacher, R.M. Goldberg, S. O'Reilly, L. Chu, C.A. Azar, S. Lopa, and N. Wolmark Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 J. Clin. Oncol. 29 2011 11 16
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 11-16
-
-
Allegra, C.J.1
Yothers, G.2
O'Connell, M.J.3
Sharif, S.4
Petrelli, N.J.5
Colangelo, L.H.6
Atkins, J.N.7
Seay, T.E.8
Fehrenbacher, L.9
Goldberg, R.M.10
O'Reilly, S.11
Chu, L.12
Azar, C.A.13
Lopa, S.14
Wolmark, N.15
-
49
-
-
84870244259
-
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial
-
A. de Gramont, E. Van Cutsem, H.J. Schmoll, J. Tabernero, S. Clarke, M.J. Moore, D. Cunningham, T.H. Cartwright, J.R. Hecht, F. Rivera, S.A. Im, G. Bodoky, R. Salazar, F. Maindrault-Goebel, E. Shacham-Shmueli, E. Bajetta, M. Makrutzki, A. Shang, T. Andre, and P.M. Hoff Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial Lancet Oncol. 13 2012 1225 1233
-
(2012)
Lancet Oncol.
, vol.13
, pp. 1225-1233
-
-
De Gramont, A.1
Van Cutsem, E.2
Schmoll, H.J.3
Tabernero, J.4
Clarke, S.5
Moore, M.J.6
Cunningham, D.7
Cartwright, T.H.8
Hecht, J.R.9
Rivera, F.10
Im, S.A.11
Bodoky, G.12
Salazar, R.13
Maindrault-Goebel, F.14
Shacham-Shmueli, E.15
Bajetta, E.16
Makrutzki, M.17
Shang, A.18
Andre, T.19
Hoff, P.M.20
more..
-
50
-
-
79551520348
-
Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis
-
V. Ranpura, S. Hapani, and S. Wu Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis J. Am. Med. Assoc. 305 2011 487 494
-
(2011)
J. Am. Med. Assoc.
, vol.305
, pp. 487-494
-
-
Ranpura, V.1
Hapani, S.2
Wu, S.3
-
51
-
-
43249095919
-
Tumor angiogenesis
-
DOI 10.1056/NEJMra0706596
-
R.S. Kerbel Tumor angiogenesis N. Engl. J. Med. 358 2008 2039 2049 (Pubitemid 351656458)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.19
, pp. 2039-2049
-
-
Kerbel, R.S.1
-
52
-
-
79951983770
-
Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials
-
D. Miles, N. Harbeck, B. Escudier, H. Hurwitz, L. Saltz, E. Van Cutsem, J. Cassidy, B. Mueller, and F. Sirzen Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials J. Clin. Oncol. 29 2011 83 88
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 83-88
-
-
Miles, D.1
Harbeck, N.2
Escudier, B.3
Hurwitz, H.4
Saltz, L.5
Van Cutsem, E.6
Cassidy, J.7
Mueller, B.8
Sirzen, F.9
-
53
-
-
77953467629
-
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study
-
H.J. Hammers, H.M. Verheul, B. Salumbides, R. Sharma, M. Rudek, J. Jaspers, P. Shah, L. Ellis, L. Shen, S. Paesante, K. Dykema, K. Furge, B.T. Teh, G. Netto, and R. Pili Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol. Cancer Ther. 9 2010 1525 1535
-
(2010)
Mol. Cancer Ther.
, vol.9
, pp. 1525-1535
-
-
Hammers, H.J.1
Verheul, H.M.2
Salumbides, B.3
Sharma, R.4
Rudek, M.5
Jaspers, J.6
Shah, P.7
Ellis, L.8
Shen, L.9
Paesante, S.10
Dykema, K.11
Furge, K.12
Teh, B.T.13
Netto, G.14
Pili, R.15
-
54
-
-
84861525048
-
Therapeutic targeting of BCR-ABL: Prognostic markers of response and resistance mechanism in chronic myeloid leukaemia
-
D.T. Yeung, and T.P. Hughes Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia Crit. Rev. Oncog. 17 2012 17 30
-
(2012)
Crit. Rev. Oncog.
, vol.17
, pp. 17-30
-
-
Yeung, D.T.1
Hughes, T.P.2
-
55
-
-
18844428327
-
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
-
DOI 10.1016/j.cell.2005.02.034, PII S0092867405002370
-
A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 121 2005 335 348 (Pubitemid 40692295)
-
(2005)
Cell
, vol.121
, Issue.3
, pp. 335-348
-
-
Orimo, A.1
Gupta, P.B.2
Sgroi, D.C.3
Arenzana-Seisdedos, F.4
Delaunay, T.5
Naeem, R.6
Carey, V.J.7
Richardson, A.L.8
Weinberg, R.A.9
-
56
-
-
26644471951
-
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
-
DOI 10.1016/j.ccr.2005.09.005, PII S1535610805002989
-
O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
-
(2005)
Cancer Cell
, vol.8
, Issue.4
, pp. 299-309
-
-
Casanovas, O.1
Hicklin, D.J.2
Bergers, G.3
Hanahan, D.4
-
57
-
-
57849106330
-
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment
-
Y. Crawford, I. Kasman, L. Yu, C. Zhong, X. Wu, Z. Modrusan, J. Kaminker, and N. Ferrara PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment Cancer Cell 15 2009 21 34
-
(2009)
Cancer Cell
, vol.15
, pp. 21-34
-
-
Crawford, Y.1
Kasman, I.2
Yu, L.3
Zhong, C.4
Wu, X.5
Modrusan, Z.6
Kaminker, J.7
Ferrara, N.8
-
58
-
-
79957921039
-
Growing tumor vessels: More than one way to skin a cat - Implications for angiogenesis targeted cancer therapies
-
R. Leite de Oliveira, A. Hamm, and M. Mazzone Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies Mol. Aspects Med. 32 2011 71 87
-
(2011)
Mol. Aspects Med.
, vol.32
, pp. 71-87
-
-
Leite De Oliveira, R.1
Hamm, A.2
Mazzone, M.3
-
59
-
-
79953313814
-
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
-
T. Cascone, M.H. Herynk, L. Xu, Z. Du, H. Kadara, M.B. Nilsson, C.J. Oborn, Y.Y. Park, B. Erez, J.J. Jacoby, J.S. Lee, H.Y. Lin, F. Ciardiello, R.S. Herbst, R.R. Langley, and J.V. Heymach Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma J. Clin. Invest. 121 2011 1313 1328
-
(2011)
J. Clin. Invest.
, vol.121
, pp. 1313-1328
-
-
Cascone, T.1
Herynk, M.H.2
Xu, L.3
Du, Z.4
Kadara, H.5
Nilsson, M.B.6
Oborn, C.J.7
Park, Y.Y.8
Erez, B.9
Jacoby, J.J.10
Lee, J.S.11
Lin, H.Y.12
Ciardiello, F.13
Herbst, R.S.14
Langley, R.R.15
Heymach, J.V.16
-
60
-
-
30944452436
-
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]
-
DOI 10.1200/JCO.2005.02.5635
-
C.G. Willett, Y. Boucher, D.G. Duda, E. di Tomaso, L.L. Munn, R.T. Tong, S.V. Kozin, L. Petit, R.K. Jain, D.C. Chung, D.V. Sahani, S.P. Kalva, K.S. Cohen, D.T. Scadden, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, P.C. Shellito, M. Mino-Kenudson, and G.Y. Lauwers Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J. Clin. Oncol. 23 2005 8136 8139 (Pubitemid 46657433)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.31
, pp. 8136-8139
-
-
Willett, C.G.1
Boucher, Y.2
Duda, D.G.3
Di Tomaso, E.4
Munn, L.L.5
Tong, R.T.6
Kozin, S.V.7
Petit, L.8
Jain, R.K.9
Chung, D.C.10
Sahani, D.V.11
Kalva, S.P.12
Cohen, K.S.13
Scadden, D.T.14
Fischman, A.J.15
Clark, J.W.16
Ryan, D.P.17
Zhu, A.X.18
Blaszkowsky, L.S.19
Shellito, P.C.20
Mino-Kenudson, M.21
Lauwers, G.Y.22
more..
-
61
-
-
33846821872
-
Targeted therapy for metastatic renal cell carcinoma
-
DOI 10.1200/JCO.2006.08.5415
-
R.J. Motzer, and R.M. Bukowski Targeted therapy for metastatic renal cell carcinoma J. Clin. Oncol. 24 2006 5601 5608 (Pubitemid 46631341)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.35
, pp. 5601-5608
-
-
Motzer, R.J.1
Bukowski, R.M.2
-
62
-
-
33749441325
-
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
-
DOI 10.1172/JCI24612
-
M.R. Mancuso, R. Davis, S.M. Norberg, S. O'Brien, B. Sennino, T. Nakahara, V.J. Yao, T. Inai, P. Brooks, B. Freimark, D.R. Shalinsky, D.D. Hu-Lowe, and D.M. McDonald Rapid vascular regrowth in tumors after reversal of VEGF inhibition J. Clin. Invest. 116 2006 2610 2621 (Pubitemid 44511625)
-
(2006)
Journal of Clinical Investigation
, vol.116
, Issue.10
, pp. 2610-2621
-
-
Mancuso, M.R.1
Davis, R.2
Norberg, S.M.3
O'Brien, S.4
Sennino, B.5
Nakahara, T.6
Yao, V.J.7
Inai, T.8
Brooks, P.9
Freimark, B.10
Shalinsky, D.R.11
Hu-Lowe, D.D.12
McDonald, D.M.13
-
63
-
-
33846149645
-
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
-
DOI 10.1016/j.ccr.2006.11.021, PII S1535610806003709
-
T.T. Batchelor, A.G. Sorensen, E. di Tomaso, W.T. Zhang, D.G. Duda, K.S. Cohen, K.R. Kozak, D.P. Cahill, P.J. Chen, M. Zhu, M. Ancukiewicz, M.M. Mrugala, S. Plotkin, J. Drappatz, D.N. Louis, P. Ivy, D.T. Scadden, T. Benner, J.S. Loeffler, P.Y. Wen, and R.K. Jain AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95 (Pubitemid 46075199)
-
(2007)
Cancer Cell
, vol.11
, Issue.1
, pp. 83-95
-
-
Batchelor, T.T.1
Sorensen, A.G.2
Di Tomaso, E.3
Zhang, W.-T.4
Duda, D.G.5
Cohen, K.S.6
Kozak, K.R.7
Cahill, D.P.8
Chen, P.-J.9
Zhu, M.10
Ancukiewicz, M.11
Mrugala, M.M.12
Plotkin, S.13
Drappatz, J.14
Louis, D.N.15
Ivy, P.16
Scadden, DavidT.17
Benner, T.18
Loeffler, J.S.19
Wen, P.Y.20
Jain, R.K.21
more..
-
64
-
-
54549123309
-
VEGF-A splicing: The key to anti-angiogenic therapeutics?
-
S.J. Harper, and D.O. Bates VEGF-A splicing: The key to anti-angiogenic therapeutics? Nat. Rev. Cancer 8 2008 880 887
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 880-887
-
-
Harper, S.J.1
Bates, D.O.2
-
65
-
-
0037098860
-
165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma
-
D.O. Bates, T.G. Cui, J.M. Doughty, M. Winkler, M. Sugiono, J.D. Shields, D. Peat, D. Gillatt, and S.J. Harper VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res. 62 2002 4123 4131 (Pubitemid 34791084)
-
(2002)
Cancer Research
, vol.62
, Issue.14
, pp. 4123-4131
-
-
Bates, D.O.1
Cui, T.-G.2
Doughty, J.M.3
Winkler, M.4
Sugiono, M.5
Shields, J.D.6
Peat, D.7
Gillatt, D.8
Harper, S.J.9
-
66
-
-
42149152015
-
165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: Balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
-
DOI 10.1038/sj.bjc.6604308, PII 6604308
-
A.H. Varey, E.S. Rennel, Y. Qiu, H.S. Bevan, R.M. Perrin, S. Raffy, A.R. Dixon, C. Paraskeva, O. Zaccheo, A.B. Hassan, S.J. Harper, and D.O. Bates VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy Br. J. Cancer 98 2008 1366 1379 (Pubitemid 351543576)
-
(2008)
British Journal of Cancer
, vol.98
, Issue.8
, pp. 1366-1379
-
-
Varey, A.H.R.1
Rennel, E.S.2
Qiu, Y.3
Bevan, H.S.4
Perrin, R.M.5
Raffy, S.6
Dixon, A.R.7
Paraskeva, C.8
Zaccheo, O.9
Hassan, A.B.10
Harper, S.J.11
Bates, D.O.12
-
67
-
-
78650656872
-
VEGF(1)(2)(1)b and VEGF(1)(6)(5)b are weakly angiogenic isoforms of VEGF-A
-
R. Catena, L. Larzabal, M. Larrayoz, E. Molina, J. Hermida, J. Agorreta, R. Montes, R. Pio, L.M. Montuenga, and A. Calvo VEGF(1)(2)(1)b and VEGF(1)(6)(5)b are weakly angiogenic isoforms of VEGF-A Mol. Cancer 9 2010 320
-
(2010)
Mol. Cancer
, vol.9
, pp. 320
-
-
Catena, R.1
Larzabal, L.2
Larrayoz, M.3
Molina, E.4
Hermida, J.5
Agorreta, J.6
Montes, R.7
Pio, R.8
Montuenga, L.M.9
Calvo, A.10
-
68
-
-
84860442891
-
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale
-
S. Harris, M. Craze, J. Newton, M. Fisher, D.T. Shima, G.M. Tozer, and C. Kanthou Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale PLoS One 7 2012 e35231
-
(2012)
PLoS One
, vol.7
, pp. 35231
-
-
Harris, S.1
Craze, M.2
Newton, J.3
Fisher, M.4
Shima, D.T.5
Tozer, G.M.6
Kanthou, C.7
-
69
-
-
84859423059
-
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: The role of CXCL cytokines
-
R. Grepin, M. Guyot, M. Jacquin, J. Durivault, E. Chamorey, A. Sudaka, C. Serdjebi, B. Lacarelle, J.Y. Scoazec, S. Negrier, H. Simonnet, and G. Pages Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: The role of CXCL cytokines Oncogene 31 2012 1683 1694
-
(2012)
Oncogene
, vol.31
, pp. 1683-1694
-
-
Grepin, R.1
Guyot, M.2
Jacquin, M.3
Durivault, J.4
Chamorey, E.5
Sudaka, A.6
Serdjebi, C.7
Lacarelle, B.8
Scoazec, J.Y.9
Negrier, S.10
Simonnet, H.11
Pages, G.12
-
70
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
M. Paez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Vinals, M. Inoue, G. Bergers, D. Hanahan, and O. Casanovas Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Paez-Ribes, M.1
Allen, E.2
Hudock, J.3
Takeda, T.4
Okuyama, H.5
Vinals, F.6
Inoue, M.7
Bergers, G.8
Hanahan, D.9
Casanovas, O.10
-
71
-
-
58149456505
-
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
-
R.M. Zuniga, R. Torcuator, R. Jain, J. Anderson, T. Doyle, S. Ellika, L. Schultz, and T. Mikkelsen Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J. Neurooncol. 91 2009 329 336
-
(2009)
J. Neurooncol.
, vol.91
, pp. 329-336
-
-
Zuniga, R.M.1
Torcuator, R.2
Jain, R.3
Anderson, J.4
Doyle, T.5
Ellika, S.6
Schultz, L.7
Mikkelsen, T.8
-
72
-
-
84862776792
-
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
-
F. Shojaei, B.H. Simmons, J.H. Lee, P.B. Lappin, and J.G. Christensen HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis Cancer Lett. 320 2012 48 55
-
(2012)
Cancer Lett.
, vol.320
, pp. 48-55
-
-
Shojaei, F.1
Simmons, B.H.2
Lee, J.H.3
Lappin, P.B.4
Christensen, J.G.5
-
73
-
-
34547107592
-
Hypoxia-driven selection of the metastatic phenotype
-
DOI 10.1007/s10555-007-9062-2, Special issue on Hypoxia and Cancer, Guest Editor: Gregg L. Semenza
-
R. Sullivan, and C.H. Graham Hypoxia-driven selection of the metastatic phenotype Cancer Metastasis Rev. 26 2007 319 331 (Pubitemid 47101665)
-
(2007)
Cancer and Metastasis Reviews
, vol.26
, Issue.2
, pp. 319-331
-
-
Sullivan, R.1
Graham, C.H.2
-
74
-
-
40249113328
-
Direct regulation of TWIST by HIF-1alpha promotes metastasis
-
M.H. Yang, M.Z. Wu, S.H. Chiou, P.M. Chen, S.Y. Chang, C.J. Liu, S.C. Teng, and K.J. Wu Direct regulation of TWIST by HIF-1alpha promotes metastasis Nat. Cell Biol. 10 2008 295 305
-
(2008)
Nat. Cell Biol.
, vol.10
, pp. 295-305
-
-
Yang, M.H.1
Wu, M.Z.2
Chiou, S.H.3
Chen, P.M.4
Chang, S.Y.5
Liu, C.J.6
Teng, S.C.7
Wu, K.J.8
-
75
-
-
34247527730
-
Hypoxia-Inducible Factors, Stem Cells, and Cancer
-
DOI 10.1016/j.cell.2007.04.019, PII S0092867407005259
-
B. Keith, and M.C. Simon Hypoxia-inducible factors, stem cells, and cancer Cell 129 2007 465 472 (Pubitemid 46660978)
-
(2007)
Cell
, vol.129
, Issue.3
, pp. 465-472
-
-
Keith, B.1
Simon, M.C.2
-
76
-
-
78650098659
-
Glioblastoma stem-like cells give rise to tumour endothelium
-
R. Wang, K. Chadalavada, J. Wilshire, U. Kowalik, K.E. Hovinga, A. Geber, B. Fligelman, M. Leversha, C. Brennan, and V. Tabar Glioblastoma stem-like cells give rise to tumour endothelium Nature 468 2010 829 833
-
(2010)
Nature
, vol.468
, pp. 829-833
-
-
Wang, R.1
Chadalavada, K.2
Wilshire, J.3
Kowalik, U.4
Hovinga, K.E.5
Geber, A.6
Fligelman, B.7
Leversha, M.8
Brennan, C.9
Tabar, V.10
-
77
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
Lee, C.R.2
Cruz-Munoz, W.3
Bjarnason, G.A.4
Christensen, J.G.5
Kerbel, R.S.6
-
78
-
-
77956503727
-
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres
-
E.E. Bar, A. Lin, V. Mahairaki, W. Matsui, and C.G. Eberhart Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres Am. J. Pathol. 177 2010 1491 1502
-
(2010)
Am. J. Pathol.
, vol.177
, pp. 1491-1502
-
-
Bar, E.E.1
Lin, A.2
Mahairaki, V.3
Matsui, W.4
Eberhart, C.G.5
-
79
-
-
84857407549
-
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
-
S.J. Conley, E. Gheordunescu, P. Kakarala, B. Newman, H. Korkaya, A.N. Heath, S.G. Clouthier, and M.S. Wicha Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia Proc. Natl. Acad. Sci. U. S. A. 109 2012 2784 2789
-
(2012)
Proc. Natl. Acad. Sci. U. S. A.
, vol.109
, pp. 2784-2789
-
-
Conley, S.J.1
Gheordunescu, E.2
Kakarala, P.3
Newman, B.4
Korkaya, H.5
Heath, A.N.6
Clouthier, S.G.7
Wicha, M.S.8
-
80
-
-
84859385707
-
Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma
-
Y.L. Hu, M. DeLay, A. Jahangiri, A.M. Molinaro, S.D. Rose, W.S. Carbonell, and M.K. Aghi Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma Cancer Res. 72 2012 1773 1783
-
(2012)
Cancer Res.
, vol.72
, pp. 1773-1783
-
-
Hu, Y.L.1
Delay, M.2
Jahangiri, A.3
Molinaro, A.M.4
Rose, S.D.5
Carbonell, W.S.6
Aghi, M.K.7
-
81
-
-
77950800322
-
Role of hypoxia and autophagy in MDA-MB-231 invasiveness
-
M. Indelicato, B. Pucci, L. Schito, V. Reali, M. Aventaggiato, M.C. Mazzarino, F. Stivala, M. Fini, M.A. Russo, and M. Tafani Role of hypoxia and autophagy in MDA-MB-231 invasiveness J. Cell. Physiol. 223 2010 359 368
-
(2010)
J. Cell. Physiol.
, vol.223
, pp. 359-368
-
-
Indelicato, M.1
Pucci, B.2
Schito, L.3
Reali, V.4
Aventaggiato, M.5
Mazzarino, M.C.6
Stivala, F.7
Fini, M.8
Russo, M.A.9
Tafani, M.10
-
82
-
-
82555189379
-
Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance
-
K.J. Gotink, H.J. Broxterman, M. Labots, R.R. de Haas, H. Dekker, R.J. Honeywell, M.A. Rudek, L.V. Beerepoot, R.J. Musters, G. Jansen, A.W. Griffioen, Y.G. Assaraf, R. Pili, G.J. Peters, and H.M. Verheul Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance Clin. Cancer Res. 17 2011 7337 7346
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 7337-7346
-
-
Gotink, K.J.1
Broxterman, H.J.2
Labots, M.3
De Haas, R.R.4
Dekker, H.5
Honeywell, R.J.6
Rudek, M.A.7
Beerepoot, L.V.8
Musters, R.J.9
Jansen, G.10
Griffioen, A.W.11
Assaraf, Y.G.12
Pili, R.13
Peters, G.J.14
Verheul, H.M.15
-
83
-
-
0026485002
-
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
-
D. Shweiki, A. Itin, D. Soffer, and E. Keshet Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843 945
-
(1992)
Nature
, vol.359
, pp. 843-945
-
-
Shweiki, D.1
Itin, A.2
Soffer, D.3
Keshet, E.4
-
84
-
-
0033580889
-
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
-
DOI 10.1126/science.284.5422.1994
-
J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, G.D. Yancopoulos, and S.J. Wiegand Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998 (Pubitemid 29309448)
-
(1999)
Science
, vol.284
, Issue.5422
, pp. 1994-1998
-
-
Holash, J.1
Maisonpierre, P.C.2
Compton, D.3
Boland, P.4
Alexander, C.R.5
Zagzag, D.6
Yancopoulos, G.D.7
Wiegand, S.J.8
-
85
-
-
33645504221
-
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells
-
M. Calvani, A. Rapisarda, B. Uranchimeg, R.H. Shoemaker, and G. Melillo Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells Blood 107 2006 2705 2712
-
(2006)
Blood
, vol.107
, pp. 2705-2712
-
-
Calvani, M.1
Rapisarda, A.2
Uranchimeg, B.3
Shoemaker, R.H.4
Melillo, G.5
-
86
-
-
33744959141
-
Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1
-
DOI 10.1074/jbc.M602003200
-
H. Okuyama, B. Krishnamachary, Y.F. Zhou, H. Nagasawa, M. Bosch-Marce, and G.L. Semenza Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1 J. Biol. Chem. 281 2006 15554 15563 (Pubitemid 43855148)
-
(2006)
Journal of Biological Chemistry
, vol.281
, Issue.22
, pp. 15554-15563
-
-
Okuyama, H.1
Krishnamachary, B.2
Zhou, Y.F.3
Nagasawa, H.4
Bosch-Marce, M.5
Semenza, G.L.6
-
87
-
-
0035160312
-
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
-
DOI 10.1038/nm1101-1194
-
D. Lyden, K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. Heissig, W. Marks, L. Witte, Y. Wu, D. Hicklin, Z. Zhu, N.R. Hackett, R.G. Crystal, M.A. Moore, K.A. Hajjar, K. Manova, R. Benezra, and S. Rafii Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat. Med. 7 2001 1194 1201 (Pubitemid 33063774)
-
(2001)
Nature Medicine
, vol.7
, Issue.11
, pp. 1194-1201
-
-
Lyden, D.1
Hattori, K.2
Dias, S.3
Costa, C.4
Blaikie, P.5
Butros, L.6
Chadburn, A.7
Heissig, B.8
Marks, W.9
Witte, L.10
Wu, Y.11
Hicklin, D.12
Zhu, Z.13
Hackett, N.R.14
Crystal, R.G.15
Moore, M.A.S.16
Hajjar, K.A.17
Manova, K.18
Benezra, R.19
Rafii, S.20
more..
-
88
-
-
18444389451
-
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand
-
DOI 10.1016/S0092-8674(02)00754-7
-
B. Heissig, K. Hattori, S. Dias, M. Friedrich, B. Ferris, N.R. Hackett, R.G. Crystal, P. Besmer, D. Lyden, M.A. Moore, Z. Werb, and S. Rafii Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand Cell 109 2002 625 637 (Pubitemid 34628725)
-
(2002)
Cell
, vol.109
, Issue.5
, pp. 625-637
-
-
Heissig, B.1
Hattori, K.2
Dias, S.3
Friedrich, M.4
Ferris, B.5
Hackett, N.R.6
Crystal, R.G.7
Besmer, P.8
Lyden, D.9
Moore, M.A.S.10
Werb, Z.11
Rafii, S.12
-
89
-
-
0036831559
-
Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
-
DOI 10.1038/nrc925
-
S. Rafii, D. Lyden, R. Benezra, K. Hattori, and B. Heissig Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2 2002 826 835 (Pubitemid 37328901)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.11
, pp. 826-835
-
-
Rafii, S.1
Lyden, D.2
Benezra, R.3
Hattori, K.4
Heissig, B.5
-
90
-
-
4644295385
-
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells
-
DOI 10.1182/blood-2004-01-0336
-
I. Rajantie, M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo, and P. Salven Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells Blood 104 2004 2084 2086 (Pubitemid 39297861)
-
(2004)
Blood
, vol.104
, Issue.7
, pp. 2084-2086
-
-
Rajantie, I.1
Ilmonen, M.2
Alminaite, A.3
Ozerdem, U.4
Alitalo, K.5
Salven, P.6
-
91
-
-
28444451122
-
Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors
-
DOI 10.1016/j.ymthe.2005.07.693, PII S1525001605014310
-
M. Aghi, and E.A. Chiocca Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors Mol. Ther. 12 2005 994 1005 (Pubitemid 41723033)
-
(2005)
Molecular Therapy
, vol.12
, Issue.6
, pp. 994-1005
-
-
Aghi, M.1
Chiocca, E.A.2
-
92
-
-
26944437515
-
+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival
-
DOI 10.1038/ncb1288, PII N1288
-
S. Song, A.J. Ewald, W. Stallcup, Z. Werb, and G. Bergers PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival Nat. Cell Biol. 7 2005 870 879 (Pubitemid 41486287)
-
(2005)
Nature Cell Biology
, vol.7
, Issue.9
, pp. 870-879
-
-
Song, S.1
Ewald, A.J.2
Stallcup, W.3
Werb, Z.4
Bergers, G.5
-
93
-
-
24944587964
-
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
-
DOI 10.1016/j.ccr.2005.08.002, PII S1535610805002606
-
M. De Palma, M.A. Venneri, R. Galli, L. Sergi Sergi, L.S. Politi, M. Sampaolesi, and L. Naldini Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors Cancer Cell 8 2005 211 226 (Pubitemid 41317592)
-
(2005)
Cancer Cell
, vol.8
, Issue.3
, pp. 211-226
-
-
De Palma, M.1
Venneri, M.A.2
Galli, R.3
Sergi, L.S.4
Politi, L.S.5
Sampaolesi, M.6
Naldini, L.7
-
94
-
-
30344437303
-
VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells
-
DOI 10.1016/j.cell.2005.10.036, PII S0092867405012742
-
M. Grunewald, I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Jung, S. Chimenti, L. Landsman, R. Abramovitch, and E. Keshet VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells Cell 124 2006 175 189 (Pubitemid 43069318)
-
(2006)
Cell
, vol.124
, Issue.1
, pp. 175-189
-
-
Grunewald, M.1
Avraham, I.2
Dor, Y.3
Bachar-Lustig, E.4
Itin, A.5
Yung, S.6
Chimenti, S.7
Landsman, L.8
Abramovitch, R.9
Keshet, E.10
-
95
-
-
33845314302
-
Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization
-
DOI 10.1172/JCI29314
-
H.G. Kopp, A.T. Hooper, M.J. Broekman, S.T. Avecilla, I. Petit, M. Luo, T. Milde, C.A. Ramos, F. Zhang, T. Kopp, P. Bornstein, D.K. Jin, A.J. Marcus, and S. Rafii Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization J. Clin. Invest. 116 2006 3277 3291 (Pubitemid 44878642)
-
(2006)
Journal of Clinical Investigation
, vol.116
, Issue.12
, pp. 3277-3291
-
-
Kopp, H.-G.1
Hooper, A.T.2
Broekman, M.J.3
Avecilla, S.T.4
Petit, I.5
Luo, M.6
Milde, T.7
Ramos, C.A.8
Zhang, F.9
Kopp, T.10
Bornstein, P.11
Jin, D.K.12
Marcus, A.J.13
Rafii, S.14
-
96
-
-
19944422751
-
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases
-
DOI 10.1016/j.ccr.2004.10.011, PII S1535610804003058
-
F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, L. Xu, D.J. Hicklin, D. Fukumura, E. di Tomaso, L.L. Munn, and R.K. Jain Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563 (Pubitemid 40017699)
-
(2004)
Cancer Cell
, vol.6
, Issue.6
, pp. 553-563
-
-
Winkler, F.1
Kozin, S.V.2
Tong, R.T.3
Chae, S.-S.4
Booth, M.F.5
Garkavtsev, I.6
Xu, L.7
Hicklin, D.J.8
Fukumura, D.9
Di Tomaso, E.10
Munn, L.L.11
Jain, R.K.12
-
97
-
-
34547820876
-
+ myeloid cells
-
DOI 10.1038/nbt1323, PII NBT1323
-
F. Shojaei, X. Wu, A.K. Malik, C. Zhong, M.E. Baldwin, S. Schanz, G. Fuh, H.P. Gerber, and N. Ferrara Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat. Biotechnol. 25 2007 911 920 (Pubitemid 47236916)
-
(2007)
Nature Biotechnology
, vol.25
, Issue.8
, pp. 911-920
-
-
Shojaei, F.1
Wu, X.2
Malik, A.K.3
Zhong, C.4
Baldwin, M.E.5
Schanz, S.6
Fuh, G.7
Gerber, H.-P.8
Ferrara, N.9
-
98
-
-
39849102836
-
HIF1alpha Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
-
DOI 10.1016/j.ccr.2008.01.034, PII S153561080800041X
-
R. Du, K.V. Lu, C. Petritsch, P. Liu, R. Ganss, E. Passegue, H. Song, S. Vandenberg, R.S. Johnson, Z. Werb, and G. Bergers HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion Cancer Cell 13 2008 206 220 (Pubitemid 351318372)
-
(2008)
Cancer Cell
, vol.13
, Issue.3
, pp. 206-220
-
-
Du, R.1
Lu, K.V.2
Petritsch, C.3
Liu, P.4
Ganss, R.5
Passegue, E.6
Song, H.7
VandenBerg, S.8
Johnson, R.S.9
Werb, Z.10
Bergers, G.11
-
99
-
-
66149092730
-
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
-
F. Shojaei, X. Wu, X. Qu, M. Kowanetz, L. Yu, M. Tan, Y.G. Meng, and N. Ferrara G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models Proc. Natl. Acad. Sci. U. S. A. 106 2009 6742 6747
-
(2009)
Proc. Natl. Acad. Sci. U. S. A.
, vol.106
, pp. 6742-6747
-
-
Shojaei, F.1
Wu, X.2
Qu, X.3
Kowanetz, M.4
Yu, L.5
Tan, M.6
Meng, Y.G.7
Ferrara, N.8
-
100
-
-
52049091826
-
Cellular interactions in the vascular niche: Implications in the regulation of tumor dormancy
-
E. Favaro, A. Amadori, and S. Indraccolo Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy Acta Pathol. Microbiol. Immunol. Scand. 116 2008 648 659
-
(2008)
Acta Pathol. Microbiol. Immunol. Scand.
, vol.116
, pp. 648-659
-
-
Favaro, E.1
Amadori, A.2
Indraccolo, S.3
-
101
-
-
70350736093
-
The angiogenic switch: Implications in the regulation of tumor dormancy
-
L. Moserle, A. Amadori, and S. Indraccolo The angiogenic switch: implications in the regulation of tumor dormancy Curr. Mol. Med. 9 2009 935 941
-
(2009)
Curr. Mol. Med.
, vol.9
, pp. 935-941
-
-
Moserle, L.1
Amadori, A.2
Indraccolo, S.3
-
102
-
-
35548936833
-
Models, mechanisms and clinical evidence for cancer dormancy
-
DOI 10.1038/nrc2256, PII NRC2256
-
J.A. Aguirre-Ghiso Models, mechanisms and clinical evidence for cancer dormancy Nat. Rev. Cancer 7 2007 834 846 (Pubitemid 350006258)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.11
, pp. 834-846
-
-
Aguirre-Ghiso, J.A.1
-
103
-
-
77953362501
-
Molecular mechanisms underlying tumor dormancy
-
N. Almog Molecular mechanisms underlying tumor dormancy Cancer Lett. 294 2010 139 146
-
(2010)
Cancer Lett.
, vol.294
, pp. 139-146
-
-
Almog, N.1
-
104
-
-
80052867880
-
ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: Opportunities to control dormant residual disease
-
M.S. Sosa, A. Avivar-Valderas, P. Bragado, H.C. Wen, and J.A. Aguirre-Ghiso ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease Clin. Cancer Res. 17 2011 5850 5857
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5850-5857
-
-
Sosa, M.S.1
Avivar-Valderas, A.2
Bragado, P.3
Wen, H.C.4
Aguirre-Ghiso, J.A.5
-
106
-
-
84874385371
-
Cancer stem cells, tumor dormancy, and metastasis
-
P. Patel, and E.I. Chen Cancer stem cells, tumor dormancy, and metastasis Front. Endocrinol. (Lausanne) 3 2012 125
-
(2012)
Front. Endocrinol. (Lausanne)
, vol.3
, pp. 125
-
-
Patel, P.1
Chen, E.I.2
-
107
-
-
0028951043
-
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
-
L. Holmgren, M.S. O'Reilly, and J. Folkman Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat. Med. 1 1995 149 153
-
(1995)
Nat. Med.
, vol.1
, pp. 149-153
-
-
Holmgren, L.1
O'Reilly, M.S.2
Folkman, J.3
-
108
-
-
0029944122
-
Angiostatin induces and sustains dormancy of human primary tumors in mice
-
DOI 10.1038/nm0696-689
-
M.S. O'Reilly, L. Holmgren, C. Chen, and J. Folkman Angiostatin induces and sustains dormancy of human primary tumors in mice Nat. Med. 2 1996 689 692 (Pubitemid 26191958)
-
(1996)
Nature Medicine
, vol.2
, Issue.6
, pp. 689-692
-
-
O'Reilly, M.S.1
Holmgren, L.2
Chen, C.3
Folkman, J.4
-
109
-
-
0347504928
-
Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases
-
DOI 10.1023/B:BREA.0000004377.12288.3c
-
G.N. Naumov, J.L. Townson, I.C. MacDonald, S.M. Wilson, V.H. Bramwell, A.C. Groom, and A.F. Chambers Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases Breast Cancer Res. Treat. 82 2003 199 206 (Pubitemid 37521976)
-
(2003)
Breast Cancer Research and Treatment
, vol.82
, Issue.3
, pp. 199-206
-
-
Naumov, G.N.1
Townson, J.L.2
MacDonald, I.C.3
Wilson, S.M.4
Bramwell, V.H.C.5
Groom, A.C.6
Chambers, A.F.7
-
110
-
-
0031038068
-
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
-
M. Relf, S. LeJeune, P.A. Scott, S. Fox, K. Smith, R. Leek, A. Moghaddam, R. Whitehouse, R. Bicknell, and A.L. Harris Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res. 57 1997 963 969 (Pubitemid 27098025)
-
(1997)
Cancer Research
, vol.57
, Issue.5
, pp. 963-969
-
-
Relf, M.1
Lejeune, S.2
Scott, P.A.E.3
Fox, S.4
Smith, K.5
Leek, R.6
Moghaddam, A.7
Whitehouse, R.8
Bicknell, R.9
Harris, A.L.10
-
111
-
-
56749174211
-
FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?
-
C. Fischer, M. Mazzone, B. Jonckx, and P. Carmeliet FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 8 2008 942 956
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 942-956
-
-
Fischer, C.1
Mazzone, M.2
Jonckx, B.3
Carmeliet, P.4
-
112
-
-
76249133170
-
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
-
D. Huang, Y. Ding, M. Zhou, B.I. Rini, D. Petillo, C.N. Qian, R. Kahnoski, P.A. Futreal, K.A. Furge, and B.T. Teh Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res. 70 2010 1063 1071
-
(2010)
Cancer Res.
, vol.70
, pp. 1063-1071
-
-
Huang, D.1
Ding, Y.2
Zhou, M.3
Rini, B.I.4
Petillo, D.5
Qian, C.N.6
Kahnoski, R.7
Futreal, P.A.8
Furge, K.A.9
Teh, B.T.10
-
113
-
-
47749109823
-
The role of CXC chemokines and their receptors in cancer
-
J. Vandercappellen, J. Van Damme, and S. Struyf The role of CXC chemokines and their receptors in cancer Cancer Lett. 267 2008 226 244
-
(2008)
Cancer Lett.
, vol.267
, pp. 226-244
-
-
Vandercappellen, J.1
Van Damme, J.2
Struyf, S.3
-
114
-
-
31544456603
-
Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma
-
DOI 10.1309/VPL5-R3JR-7F1D-6V03
-
M.L. Varney, S.L. Johansson, and R.K. Singh Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma Am. J. Clin. Pathol. 125 2006 209 216 (Pubitemid 43167161)
-
(2006)
American Journal of Clinical Pathology
, vol.125
, Issue.2
, pp. 209-216
-
-
Varney, M.L.1
Johansson, S.L.2
Singh, R.K.3
-
115
-
-
80053152480
-
Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer
-
W.L. Cheng, C.S. Wang, Y.H. Huang, M.M. Tsai, Y. Liang, and K.H. Lin Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer Ann. Oncol. 22 2011 2267 2276
-
(2011)
Ann. Oncol.
, vol.22
, pp. 2267-2276
-
-
Cheng, W.L.1
Wang, C.S.2
Huang, Y.H.3
Tsai, M.M.4
Liang, Y.5
Lin, K.H.6
-
116
-
-
33644829930
-
An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells
-
P.M. Lacal, F. Ruffini, E. Pagani, and S. D'Atri An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells Int. J. Oncol. 27 2005 1625 1632
-
(2005)
Int. J. Oncol.
, vol.27
, pp. 1625-1632
-
-
Lacal, P.M.1
Ruffini, F.2
Pagani, E.3
D'Atri, S.4
-
117
-
-
33744812156
-
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer
-
DOI 10.1016/j.lungcan.2006.02.009, PII S0169500206001735
-
T. Seto, M. Higashiyama, H. Funai, F. Imamura, K. Uematsu, N. Seki, K. Eguchi, T. Yamanaka, and Y. Ichinose Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer Lung Cancer 53 2006 91 96 (Pubitemid 43831360)
-
(2006)
Lung Cancer
, vol.53
, Issue.1
, pp. 91-96
-
-
Seto, T.1
Higashiyama, M.2
Funai, H.3
Imamura, F.4
Uematsu, K.5
Seki, N.6
Eguchi, K.7
Yamanaka, T.8
Ichinose, Y.9
-
118
-
-
33644588848
-
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer
-
G. Xia, S.R. Kumar, D. Hawes, J. Cai, L. Hassanieh, S. Groshen, S. Zhu, R. Masood, D.I. Quinn, D. Broek, J.P. Stein, and P.S. Gill Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J. Urol. 175 2006 1245 1252
-
(2006)
J. Urol.
, vol.175
, pp. 1245-1252
-
-
Xia, G.1
Kumar, S.R.2
Hawes, D.3
Cai, J.4
Hassanieh, L.5
Groshen, S.6
Zhu, S.7
Masood, R.8
Quinn, D.I.9
Broek, D.10
Stein, J.P.11
Gill, P.S.12
-
119
-
-
84863625224
-
A CXCL1 paracrine network links cancer chemoresistance and metastasis
-
S. Acharyya, T. Oskarsson, S. Vanharanta, S. Malladi, J. Kim, P.G. Morris, K. Manova-Todorova, M. Leversha, N. Hogg, V.E. Seshan, L. Norton, E. Brogi, and J. Massague A CXCL1 paracrine network links cancer chemoresistance and metastasis Cell 150 2012 165 178
-
(2012)
Cell
, vol.150
, pp. 165-178
-
-
Acharyya, S.1
Oskarsson, T.2
Vanharanta, S.3
Malladi, S.4
Kim, J.5
Morris, P.G.6
Manova-Todorova, K.7
Leversha, M.8
Hogg, N.9
Seshan, V.E.10
Norton, L.11
Brogi, E.12
Massague, J.13
-
120
-
-
76649113726
-
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
-
C. Ginestier, S. Liu, M.E. Diebel, H. Korkaya, M. Luo, M. Brown, J. Wicinski, O. Cabaud, E. Charafe-Jauffret, D. Birnbaum, J.L. Guan, G. Dontu, and M.S. Wicha CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts J. Clin. Invest. 120 2010 485 497
-
(2010)
J. Clin. Invest.
, vol.120
, pp. 485-497
-
-
Ginestier, C.1
Liu, S.2
Diebel, M.E.3
Korkaya, H.4
Luo, M.5
Brown, M.6
Wicinski, J.7
Cabaud, O.8
Charafe-Jauffret, E.9
Birnbaum, D.10
Guan, J.L.11
Dontu, G.12
Wicha, M.S.13
-
121
-
-
84888031962
-
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha
-
Y.J. Kim, H.J. Lee, T.M. Kim, T.S. Eisinger-Mathason, A.Y. Zhang, B. Schmidt, D.L. Karl, M.S. Nakazawa, P.J. Park, M.C. Simon, and S.S. Yoon Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha Int. J. Cancer 2012
-
(2012)
Int. J. Cancer
-
-
Kim, Y.J.1
Lee, H.J.2
Kim, T.M.3
Eisinger-Mathason, T.S.4
Zhang, A.Y.5
Schmidt, B.6
Karl, D.L.7
Nakazawa, M.S.8
Park, P.J.9
Simon, M.C.10
Yoon, S.S.11
-
122
-
-
80051690789
-
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition
-
E. Allen, I.B. Walters, and D. Hanahan Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition Clin. Cancer Res. 17 2011 5299 5310
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5299-5310
-
-
Allen, E.1
Walters, I.B.2
Hanahan, D.3
-
123
-
-
80053561888
-
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
-
J.A. Ledermann, A. Hackshaw, S. Kaye, G. Jayson, H. Gabra, I. McNeish, H. Earl, T. Perren, M. Gore, M. Persic, M. Adams, L. James, G. Temple, M. Merger, and G. Rustin Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J. Clin. Oncol. 29 2011 3798 3804
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 3798-3804
-
-
Ledermann, J.A.1
Hackshaw, A.2
Kaye, S.3
Jayson, G.4
Gabra, H.5
McNeish, I.6
Earl, H.7
Perren, T.8
Gore, M.9
Persic, M.10
Adams, M.11
James, L.12
Temple, G.13
Merger, M.14
Rustin, G.15
-
124
-
-
84866335646
-
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells
-
M. Taylor, F. Billiot, V. Marty, V. Rouffiac, P. Cohen, E. Tournay, P. Opolon, F. Louache, G. Vassal, C. Laplace-Builhe, P. Vielh, J.C. Soria, and F. Farace Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells Cancer Discov. 2 2012 434 449
-
(2012)
Cancer Discov.
, vol.2
, pp. 434-449
-
-
Taylor, M.1
Billiot, F.2
Marty, V.3
Rouffiac, V.4
Cohen, P.5
Tournay, E.6
Opolon, P.7
Louache, F.8
Vassal, G.9
Laplace-Builhe, C.10
Vielh, P.11
Soria, J.C.12
Farace, F.13
-
126
-
-
84868611960
-
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma
-
J. de Groot, J. Liang, L.Y. Kong, J. Wei, Y. Piao, G. Fuller, W. Qiao, and A.B. Heimberger Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma Oncotarget 3 2012 1036 1048
-
(2012)
Oncotarget
, vol.3
, pp. 1036-1048
-
-
De Groot, J.1
Liang, J.2
Kong, L.Y.3
Wei, J.4
Piao, Y.5
Fuller, G.6
Qiao, W.7
Heimberger, A.B.8
-
127
-
-
84863704553
-
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors
-
B. Sennino, T. Ishiguro-Oonuma, Y. Wei, R.M. Naylor, C.W. Williamson, V. Bhagwandin, S.P. Tabruyn, W.K. You, H.A. Chapman, J.G. Christensen, D.T. Aftab, and D.M. McDonald Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors Cancer Discov. 2 2012 270 287
-
(2012)
Cancer Discov.
, vol.2
, pp. 270-287
-
-
Sennino, B.1
Ishiguro-Oonuma, T.2
Wei, Y.3
Naylor, R.M.4
Williamson, C.W.5
Bhagwandin, V.6
Tabruyn, S.P.7
You, W.K.8
Chapman, H.A.9
Christensen, J.G.10
Aftab, D.T.11
McDonald, D.M.12
-
128
-
-
34249073831
-
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor
-
DOI 10.1158/1078-0432.CCR-06-0919
-
A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S.E. DePrimo, D.R. Shalinsky, G.D. Demetri, and J.V. Heymach Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor Clin. Cancer Res. 13 2007 2643 2650 (Pubitemid 46788031)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.9
, pp. 2643-2650
-
-
Norden-Zfoni, A.1
Desai, J.2
Manola, J.3
Beaudry, P.4
Force, J.5
Maki, R.6
Folkman, J.7
Bello, C.8
Baum, C.9
DePrimo, S.E.10
Shalinsky, D.R.11
Demetri, G.D.12
Heymach, J.V.13
-
129
-
-
78651397295
-
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment
-
W.B. Nagengast, M.N. Lub-de Hooge, S.F. Oosting, W.F. den Dunnen, F.J. Warnders, A.H. Brouwers, J.R. de Jong, P.M. Price, H. Hollema, G.A. Hospers, P.H. Elsinga, J.W. Hesselink, J.A. Gietema, and E.G. de Vries VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment Cancer Res. 71 2011 143 153
-
(2011)
Cancer Res.
, vol.71
, pp. 143-153
-
-
Nagengast, W.B.1
Lub-De Hooge, M.N.2
Oosting, S.F.3
Den Dunnen, W.F.4
Warnders, F.J.5
Brouwers, A.H.6
De Jong, J.R.7
Price, P.M.8
Hollema, H.9
Hospers, G.A.10
Elsinga, P.H.11
Hesselink, J.W.12
Gietema, J.A.13
De Vries, E.G.14
-
130
-
-
58549106152
-
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor
-
J.O. Prior, M. Montemurro, M.V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A.B. Delaloye, and S. Leyvraz Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor J. Clin. Oncol. 27 2009 439 445
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 439-445
-
-
Prior, J.O.1
Montemurro, M.2
Orcurto, M.V.3
Michielin, O.4
Luthi, F.5
Benhattar, J.6
Guillou, L.7
Elsig, V.8
Stupp, R.9
Delaloye, A.B.10
Leyvraz, S.11
-
131
-
-
79955767772
-
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
-
B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, M.E. Gore, R.A. Figlin, M.S. Baum, and R.J. Motzer Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J. Natl. Cancer Inst. 103 2011 763 773
-
(2011)
J. Natl. Cancer Inst.
, vol.103
, pp. 763-773
-
-
Rini, B.I.1
Cohen, D.P.2
Lu, D.R.3
Chen, I.4
Hariharan, S.5
Gore, M.E.6
Figlin, R.A.7
Baum, M.S.8
Motzer, R.J.9
-
132
-
-
82455199216
-
Final overall survival results and effect of prolonged (>/=1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial
-
I. Smith, J.Y. Pierga, L. Biganzoli, H. Cortes-Funes, C. Thomssen, S. Saracchini, B. Nisenbaum, I. Pelaez, A.A. Duenne, and K.I. Pritchard Final overall survival results and effect of prolonged (>/=1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial Breast Cancer Res. Treat. 130 2011 133 143
-
(2011)
Breast Cancer Res. Treat.
, vol.130
, pp. 133-143
-
-
Smith, I.1
Pierga, J.Y.2
Biganzoli, L.3
Cortes-Funes, H.4
Thomssen, C.5
Saracchini, S.6
Nisenbaum, B.7
Pelaez, I.8
Duenne, A.A.9
Pritchard, K.I.10
-
133
-
-
53749093040
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
-
B.P. Schneider, M. Wang, M. Radovich, G.W. Sledge, S. Badve, A. Thor, D.A. Flockhart, B. Hancock, N. Davidson, J. Gralow, M. Dickler, E.A. Perez, M. Cobleigh, T. Shenkier, S. Edgerton, and K.D. Miller Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J. Clin. Oncol. 26 2008 4672 4678
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 4672-4678
-
-
Schneider, B.P.1
Wang, M.2
Radovich, M.3
Sledge, G.W.4
Badve, S.5
Thor, A.6
Flockhart, D.A.7
Hancock, B.8
Davidson, N.9
Gralow, J.10
Dickler, M.11
Perez, E.A.12
Cobleigh, M.13
Shenkier, T.14
Edgerton, S.15
Miller, K.D.16
|